87 results
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
2 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
4:10pm
integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
22 Feb 24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:10pm
solid tumors at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
As previously disclosed, the company … of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately
424B7
s5hg8s32mo41h5
10 Jan 24
Prospectus with selling stockholder info
9:22am
8-K
EX-99.1
450gso
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.2
queww tjo
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
424B7
u2uqf8n5hqccn82
16 Nov 23
Prospectus with selling stockholder info
4:16pm
8-K
EX-99.1
jauf4a42wq2
2 Nov 23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.1
l09y5hkl27
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
mszxo
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
fqggghnr88nk7bi tq
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.2
lkm1orh2
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
vl2 8w0rc85rhdegup
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm